|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM189641843 |
| 003 |
DE-627 |
| 005 |
20231223184000.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2009 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2009.05.018
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0632.xml
|
| 035 |
|
|
|a (DE-627)NLM189641843
|
| 035 |
|
|
|a (NLM)19564135
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Morshed, Sufi R
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Beta-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus
|
| 264 |
|
1 |
|c 2009
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 01.09.2009
|
| 500 |
|
|
|a Date Revised 20.10.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a NZB/W female mice spontaneously develop systemic lupus, an autoantibody mediated disease associated with immune complex glomerulonephritis. Natural killer (NK) T cells augment anti-dsDNA antibody secretion by NZB/W B cells in vitro, and blocking NKT cell activation in vivo with anti-CD1 mAb ameliorates lupus disease activity. In the current study, we show that beta-galactosylceramide reduces the in vivo induction of serum IFN-gamma and/or IL-4 by the potent NKT cell agonist alpha-galactosylceramide and reduces NKT cell helper activity for IgG secretion. Treatment of NZB/W mice with the beta-galactosylceramide ameliorated lupus disease activity as judged by improvement in proteinuria, renal histopathology, IgG anti-dsDNA antibody formation, and survival. In conclusion, beta-galactosylceramide, a glycolipid that reduces the cytokine secretion induced by a potent NKT cell agonist ameliorates lupus in NZB/W mice
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antibodies, Antinuclear
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD1d
|2 NLM
|
| 650 |
|
7 |
|a Ceramides
|2 NLM
|
| 650 |
|
7 |
|a Monosaccharides
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Antigen, T-Cell
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Antigen, T-Cell, alpha-beta
|2 NLM
|
| 650 |
|
7 |
|a beta-galactosyl ceramide
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-4
|2 NLM
|
| 650 |
|
7 |
|a 207137-56-2
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Takahashi, Tsuyoshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Savage, Paul B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kambham, Neeraja
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Strober, Samuel
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 132(2009), 3 vom: 15. Sept., Seite 321-33
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:132
|g year:2009
|g number:3
|g day:15
|g month:09
|g pages:321-33
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2009.05.018
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 132
|j 2009
|e 3
|b 15
|c 09
|h 321-33
|